# Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

> **NCT04924062** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 158 (actual)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04924062
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-10
- **Primary completion:** 2022-12-15
- **Final completion:** 2025-03-25
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04924062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04924062, "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04924062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*